Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS L01B ANTIMETABOLITES L01BA Folic acid analogues L01BA04 Pemetrexed D06503 Pemetrexed sodium hydrate (JAN) <JP/US> USP drug classification [BR:br08302] Antineoplastics Antimetabolites Pemetrexed D06503 Pemetrexed sodium hydrate (JAN) Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 42 Antineoplastics 422 Antimetabolites 4229 Others D06503 Pemetrexed sodium hydrate (JAN) Drug groups [BR:br08330] Antineoplastic DG02018 Antimetabolite DG01978 Folic acid analog DG00682 Pemetrexed D06503 Pemetrexed sodium hydrate Drug classes [BR:br08332] Antineoplastic DG02018 Antimetabolite D06503 Pemetrexed sodium hydrate Target-based classification of drugs [BR:br08310] Enzymes Oxidoreductases (EC1) Dihydrofolate reductase DHFR D06503 Pemetrexed sodium hydrate (JAN) <JP/US> Transferases (EC2) Methyltransferases TYMS D06503 Pemetrexed sodium hydrate (JAN) <JP/US> Ligases (EC6) GART GART D06503 Pemetrexed sodium hydrate (JAN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D06503 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D06503 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D06503 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D06503 Drug groups [BR:br08330] Antineoplastic DG02018 Antimetabolite DG01978 Folic acid analog DG00682 Pemetrexed